Ligand id: 8707

Name: deutetrabenazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 38.77
Molecular weight 317.2
XLogP 2.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Received US FDA approval in April 2017 as a treatment for chorea (involuntary movements) arising from Huntington's disease (HD). Results from Phase 3 evaluation of the efficacy, safety and tolerability of deutetrabenazine are published in [2,5-7] (and see NCT01795859). In September 2017, deutetrabenazine received FDA approval for the treatment of tardive dyskinesia (TD; Phase 3 findings are published in [1] and [3]), joining valbenazine as an approved drug for this indication.
Mechanism Of Action and Pharmacodynamic Effects
Like tetrabenazine, deutetrabenazine inhibits the vesicular monoamine transporter 2 (SLC18A2). This decreases the amount of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine stored in presynaptic vesicles, and results in increased metabolism of the extra-vesicular neurotransmitters by monoamine oxidase. This leads to an net reduction in catecholamine-driven neuro-activity.